Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea. In the EAGLE-1 ...

Penmenvy, GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating, uncomplicated urinary tract infection were approved in the United States in the first quarter of ...

In this context, the emergence of gepotidacin represents a significant breakthrough in the fight against this disease. Gepotidacin is an oral antibiotic that works by inhibiting bacterial DNA ...

Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space. Gilead Sciences is a dominant player in the HIV market with market-leading treatments.

The US Food and Drug Administration has cleared the first-ever blood test for diagnosing Alzheimer’s disease, offering a less invasive and simpler alternative for the millions of seniors facing ...

Karyn S. Eilber, MD, discusses treatment of genitourinary syndrome of menopause. “In my experience, and probably most others, vaginal estrogen alone is probably the most effective. However, there are ...

3 Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Australia 4 Victorian Infectious Diseases Reference Laboratory, Royal ...